Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei.
Nyamyc™ (Nystatin Topical Powder, USP) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.
Published Studies Related to Nyamyc (Nystatin Cutaneous)
Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing. [2011.08]
Paecilomyces lilacinus causes multiple diseases in humans, especially in immunocompromised patients... lilacinus infection that were treated by oral voriconazole.
Clinical Trials Related to Nyamyc (Nystatin Cutaneous)
Comparing the Safety and Efficacy of Topical Gentian Violet Versus Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-Infected People in Countries Outside of the United States [Recruiting]
Oropharyngeal candidiasis (OC) is a common health issue for HIV-infected people. This study
will compare the safety and effectiveness of nystatin oral suspension versus gentian violet
(GV) for the treatment of OC.
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis [Recruiting]
The purpose of this study is to see which one of two medicines (topical gentian violet [GV]
or nystatin oral suspension) is better than the other in treating Oral Candidiasis (OC).
This will be measured by whether the study participant still has OC or sores in his/her
mouth after 14 days of treatment. Also, safety and tolerability of GV and nystatin in the
treatment of OC will be assessed.
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis [Completed]
In resource constrained societies and where HIV is a problem, oral thrush causes significant
morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are
relatively expensive compared to GV solution and ketoconazole has significant side effects
especially in association with some of the treatments for HIV related problems.
In children, either GV solutions or nystatin are used, GV is a fraction of the cost of
GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark
them out as having HIV infections. A much more dilute solution of GV has proved equally
effective in vitro and would not carry the same cosmetic problem.
In this study of children, the investigators have compared the 3 solutions, 1% GV, 0. 00165%
GV and nystatin oral drops - all masked so that they look the same - to see if GV is more
effective than nystatin, and to see if the weaker solution of GV is as effective as the
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. [Completed]
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous
nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and
clinical pharmacology of intravenous nystatin.
A Study of Nystatin in HIV-Infected Patients [Completed]
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous
nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the
safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI)
administered in an alternating regimen in this patient population.